Tompkins Financial Corp Boosts Holdings in Eli Lilly And Co (NYSE:LLY)
Tompkins Financial Corp increased its holdings in Eli Lilly And Co (NYSE:LLY) by 1.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,868 shares of the company’s stock after buying an additional 400 shares during the quarter. Tompkins Financial Corp’s holdings in Eli Lilly And Co were worth $4,085,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Trust Department MB Financial Bank N A lifted its holdings in Eli Lilly And Co by 54.7% during the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after purchasing an additional 82 shares in the last quarter. WP Advisors LLC purchased a new position in Eli Lilly And Co during the first quarter valued at approximately $38,000. Meridian Wealth Management LLC purchased a new position in Eli Lilly And Co during the first quarter valued at approximately $38,000. Ellis Investment Partners LLC purchased a new position in Eli Lilly And Co during the first quarter valued at approximately $39,000. Finally, Clarfeld Financial Advisors LLC purchased a new position in Eli Lilly And Co during the fourth quarter valued at approximately $52,000. 79.38% of the stock is currently owned by institutional investors.
In other news, SVP Christi Shaw sold 7,577 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $117.14, for a total value of $887,569.78. Following the transaction, the senior vice president now owns 500 shares of the company’s stock, valued at $58,570. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Joshua L. Smiley bought 426 shares of the stock in a transaction dated Wednesday, June 5th. The stock was bought at an average cost of $118.03 per share, for a total transaction of $50,280.78. Following the acquisition, the chief financial officer now directly owns 30,410 shares of the company’s stock, valued at approximately $3,589,292.30. The disclosure for this purchase can be found here. 0.11% of the stock is currently owned by insiders.
Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, topping the consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The firm had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.12 billion. During the same quarter in the previous year, the firm earned $1.31 earnings per share. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. As a group, equities analysts expect that Eli Lilly And Co will post 5.66 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a dividend yield of 2.38%. The ex-dividend date of this dividend is Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.
Several equities analysts have weighed in on LLY shares. ValuEngine downgraded shares of WideOpenWest from a “hold” rating to a “sell” rating in a report on Friday, June 28th. Edward Jones raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price target on the stock in a report on Tuesday, April 23rd. Barclays reaffirmed a “buy” rating and set a $140.00 price target on shares of Eli Lilly And Co in a report on Sunday, April 14th. Guggenheim lifted their price target on shares of Intuit from $260.00 to $310.00 in a report on Thursday, April 11th. Finally, TheStreet downgraded shares of Trade Desk from a “b-” rating to a “c-” rating in a report on Thursday, May 9th. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $123.49.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: How do buyers and sellers choose a strike price?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.